 NEW YORK and LEXINGTON, Mass., April 08, 2021 GLOBE NEWSWIRE -- Royalty Pharma plc Nasdaq: RPRX Royalty Pharma and Dicerna Pharmaceuticals, Inc. Nasdaq: DRNA Dicerna today announced that Royalty Pharma has acquired Dicernas royalty interest in OXLUMOTM lumasiran for an upfront cash payment of 180 million and up to 60 million in contingent sales-based milestone payments. OXLUMO, which has been approved by the U.S. Food and Drug Administration FDA and European Medicines Agency EMA for the treatment of primary hyperoxaluria PH type 1, is marketed by Alnylam Pharmaceuticals, Inc. Alnylam. 